Global Gallbladder Cancer Market Research Report – Segmentation by Treatment Type (Surgery, Radiation therapy, Chemotherapy, Immunotherapy, Targeted therapy); By Product Type (Mono therapy, Combination therapy and Mono/Combination therapy); By Molecule Type (Monoclonal Antibody, Peptides, Polymer, Small molecule); By Route of Administration (Oral, Intramuscular, Intravenous, Intratumoral, Others) Region – Size, Share, Growth Analysis |Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-16119
Format:
Region: Global
Chapter 1. GLOBAL GALLBLADDER CANCER MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. GLOBAL GALLBLADDER CANCER MARKET– Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. GLOBAL GALLBLADDER CANCER MARKET– Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. GLOBAL GALLBLADDER CANCER MARKET - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. GLOBAL GALLBLADDER CANCER MARKET- Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. GLOBAL GALLBLADDER CANCER MARKET– By Product Type
6.1. Mono Therapy
6.2. Combination Therapy
6.3. Mono/Combination Therapy
Chapter 7. GLOBAL GALLBLADDER CANCER MARKET– By Treatment Type
7.1. Surgery
7.2. Radiation therapy
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Targeted Therapy
Chapter 8. GLOBAL GALLBLADDER CANCER MARKET– By Route Of Administration
8.1. Oral
8.2. Intramuscular
8.3. Intravenous
8.4. Intertumoral (IT)
Chapter 9. GLOBAL GALLBLADDER CANCER MARKET– By Molecule Type
9.1. Monoclonal Antibody
9.2. Peptides
9.3. Polymer
9.4. Small molecule
Chapter 10. GLOBAL GALLBLADDER CANCER MARKET, By Geography – Market Size, Forecast, Trends & Insights
10.1. North America
10.1.1. By Country
10.1.1.1. U.S.A.
10.1.1.2. Canada
10.1.1.3. Mexico
10.1.2. By Product Type
10.1.3. By Treatment Type
10.1.4. By Route Of Administration
10.1.5. Molecule Type
10.1.6. Countries & Segments - Market Attractiveness Analysis
10.2. Europe
10.2.1. By Country
10.2.1.1. U.K.
10.2.1.2. Germany
10.2.1.3. France
10.2.1.4. Italy
10.2.1.5. Spain
10.2.1.6. Rest of Europe
10.2.2. By Product Type
10.2.3. By Treatment Type
10.2.4. By Route Of Adminsitration
10.2.5. Molecule Type
10.2.6. Countries & Segments - Market Attractiveness Analysis
10.3. Asia Pacific
10.3.2. By Country
10.3.2.2. China
10.3.2.2. Japan
10.3.2.3. South Korea
10.3.2.4. India
10.3.2.5. Australia & New Zealand
10.3.2.6. Rest of Asia-Pacific
10.3.2. By Product Type
10.3.3. By Treatment Type
10.3.4. By Route Of Administration
10.3.5. Molecule Type
10.3.6. Countries & Segments - Market Attractiveness Analysis
10.4. South America
10.4.3. By Country
10.4.3.3. Brazil
10.4.3.2. Argentina
10.4.3.3. Colombia
10.4.3.4. Chile
10.4.3.5. Rest of South America
10.4.2. By Product Type
10.4.3. By Treatment Type
10.4.4. By Route Of Administration
10.4.5. Molecule Type
10.4.6. Countries & Segments - Market Attractiveness Analysis
10.5. Middle East & Africa
10.5.4. By Country
10.5.4.4. United Arab Emirates (UAE)
10.5.4.2. Saudi Arabia
10.5.4.3. Qatar
10.5.4.4. Israel
10.5.4.5. South Africa
10.5.4.6. Nigeria
10.5.4.7. Kenya
10.5.4.10. Egypt
10.5.4.10. Rest of MEA
10.5.2. By Product Type
10.5.3. By Treatment Type
10.5.4. By Route Of Administration
10.6.5. Molecule Type
10.5.6. Countries & Segments - Market Attractiveness Analysis
Chapter 11. GLOBAL GALLBLADDER CANCER MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
11.1. Eli Lilly and CompanyBristol-Myers SquibbRoche
11.2. Pfizer
11.3. Novartis
11.4. Merck & Co., Inc.
11.5. Sanofi
11.6. AstraZeneca
11.7. AbbVie
11.8. Gilead Sciences
Download Sample
Choose License Type
2500
4250
5250
6900
Frequently Asked Questions
The Gallbladder Cancer Market was valued at USD 90.17 million in 2023 and is projected to reach a market size of USD 140.12 million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 6.50%.
Prevalence of cancer, Advancement in technology, Increase in awareness towards cancer and early detection, growing investment in R&D.
Based on Product Type, the Gallbladder Cancer Market is segmented into Mono therapy, Combination therapy and Mono/Combination therapy.
North America is the most dominant region for the Gallbladder Cancer Market.
Eli Lilly and Company, Bristol-Myers Squibb, Roche, Pfizer, Novartis, Merck & Co., Inc., Sanofi, AstraZeneca, AbbVie, and Gilead.
